Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More
08:36am, Sunday, 28'th Feb 2021
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Validation by the EMA of Marketing Authorization Application for Retifanlimab as a Treatment for Squamous Cell Anal Carcinoma (SCAC)
Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis
08:00am, Friday, 19'th Feb 2021
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis
Incyte: Another Buy Opportunity
09:15am, Tuesday, 16'th Feb 2021
Incyte was a buy, with share price at $85.61 in December 2020.
Incyte to Present at Upcoming Investor Conference
08:00am, Thursday, 11'th Feb 2021
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the virtual Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021 at 2:00 p.m. EST. The p
Barrick, Lyft, Nordstrom, Twitter and More Wednesday Afternoon Analyst Calls
12:33pm, Wednesday, 10'th Feb 2021
With the trading day about halfway over, the broad markets had pulled back slightly on Wednesday.
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q4 2020 Results - Earnings Call Transcript
02:35pm, Tuesday, 09'th Feb 2021
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q4 2020 Results - Earnings Call Transcript
What's Behind Incyte's Better-Than-Expected Q4 Earnings
02:00pm, Tuesday, 09'th Feb 2021
Several products contributed to the biotech's solid growth.
Incyte (INCY) Q4 Earnings and Revenues Top Estimates
09:51am, Tuesday, 09'th Feb 2021
Incyte (INCY) delivered earnings and revenue surprises of 13.41% and 17.87%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs
3 Top Growth Stocks to Buy Right Now
11:52am, Wednesday, 03'rd Feb 2021
A handful of names are shrugging off the adverse impact of the pandemic, and have the right stuff to keep on chugging.
Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib
11:22am, Monday, 01'st Feb 2021
Incyte's (INCY) pemigatinib gets positive CHMP opinion by the EMA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive CHMP opinion for Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic CCA with FGFR2 fusion or rearrangement
Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review
03:03pm, Friday, 22'nd Jan 2021
Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Squamous Cell Carcinoma of the Anal Canal (SCAC)
